AstraZeneca Plc secured an increase in product sales of 12% to $11.2 billion in the first half, confirming the strength of its new portfolio of medicines which are heavily weighted by drugs for cancer. After several years of restructuring, the company revised its guidance upward for 2019. Product sales are now expected to increase by a low double-digit percentage instead of the previously forecast high single-digit increase.
